Skip to main content
logo
Avalyn Pharma Inc. (AVLN)
NASDAQ: AVLN · Real-Time Price · USD
37.13
-1.84 (-4.72%)
Aug 20, 2026, 4:00 PM EDT - Market closed

Avalyn Pharma Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Net Income
-103.31-85.2-49.74
Depreciation & Amortization
0.20.040.08
Loss (Gain) From Sale of Assets
--0.05
Loss (Gain) From Sale of Investments
-1.74-2.35-2.58
Stock-Based Compensation
5.593.272.47
Other Operating Activities
0.370.15-
Change in Accounts Payable
1.561.40.23
Change in Other Net Operating Assets
-0.161.221.13
Operating Cash Flow
-97.48-81.48-48.37
Operating Cash Flow Growth
---

Investing Activities

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Capital Expenditures
-0.92-0.34-0.1
Investment in Securities
-40.1410.4-91.38
Investing Cash Flow
-41.0610.06-91.47

Financing Activities

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Issuance of Common Stock
320.90.020.05
Other Financing Activities
-4.94-0.59-
Financing Cash Flow
341.4499.790.09

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Net Cash Flow
202.928.36-139.75

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Free Cash Flow
-98.4-81.83-48.46
Free Cash Flow Growth
---
Free Cash Flow Per Share
-11.75-84.27-179.40
Levered Free Cash Flow
--50.58-
Unlevered Free Cash Flow
--50.58-

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Change in Working Capital
1.412.611.36
SEC Filings: 10-K · 10-Q